Mirikizumab: A promising breakthrough in Crohn's disease treatment
Muaaz Aslam1, Mohammad Haris Ali1, Hamza Irfan1
1Department of Medicine Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore Punjab Pakistan.
Insights
Mirikizumab shows significant clinical response and remission rates in Crohn's disease (CD) patients. This new therapy offers a promising alternative for managing this chronic inflammatory bowel disorder.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Crohn's disease (CD) is a chronic inflammatory bowel disorder affecting 100-300 per 100,000 individuals, primarily in Western nations.
- Symptoms include abdominal pain, diarrhea, and weight loss, with potential complications like abscesses and fistulas.
- Current treatments involve pharmaceuticals, bowel rest, surgery, and emerging biological therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of mirikizumab in treating moderately to severely active Crohn's disease.
- To compare the performance of mirikizumab against placebo and ustekinumab in clinical trials.
- To assess the impact of risankizumab in comparison to ustekinumab on inflammatory markers and remission rates.
Main Methods:
- The VIVID-1 trial assessed mirikizumab's efficacy in Crohn's disease patients.
- The SEQUENCE study compared risankizumab with ustekinumab.
- Clinical response, remission rates, and inflammatory markers were key outcome measures.
Main Results:
- Mirikizumab demonstrated significantly higher clinical response rates by Week 12 (45.4% vs. 19.6%) and clinical remission rates by Week 52 (54.1% vs. 19.6%) compared to placebo in the VIVID-1 trial.
- Mirikizumab showed non-inferiority to ustekinumab in achieving clinical remission by Week 52.
- Risankizumab exhibited superior reductions in inflammatory markers and higher biologic remission rates compared to ustekinumab in the SEQUENCE study.
- Both mirikizumab and risankizumab exhibited comparable safety profiles to ustekinumab, with common adverse events including COVID-19, anemia, and headache.
Conclusions:
- Mirikizumab presents a promising new therapeutic option for Crohn's disease, supported by significant clinical trial results.
- Further research is recommended to fully understand the long-term efficacy and safety of mirikizumab.
- Updating clinical guidelines and improving accessibility are crucial for optimizing Crohn's disease management with novel therapies.
Introduction:
Crohn's disease (CD) is a chronic, progressive inflammatory bowel disorder characterized by persistent inflammation and noncontiguous "skip lesions" throughout the gastrointestinal tract. With a prevalence of 100-300 cases per 100,000 individuals, CD is most common in Western Europe and North America. Symptoms include abdominal pain, diarrhea, fever, weight loss, and anemia, with severe cases leading to complications such as perianal abscesses and cutaneous fistulas. Treatment involves pharmaceutical interventions, bowel rest, and sometimes surgery, with biological therapies like ustekinumab and mirikizumab gaining prominence.
Clinical Trials:
The VIVID-1 trial assessed mirikizumab in patients with moderately to severely active CD. By Week 12, mirikizumab significantly outperformed placebo in clinical response (45.4% vs. 19.6%, p < 0.000001). By Week 52, it showed higher clinical remission rates (54.1% vs. 19.6%) and demonstrated non-inferiority to ustekinumab in clinical remission (p = 0.51). The SEQUENCE study compared risankizumab to ustekinumab, with risankizumab showing superior reductions in inflammatory markers and higher biologic remission rates at Weeks 8, 24, and 48. Both treatments had similar safety profiles, with common adverse events including COVID-19, anemia, and headache.
Conclusion:
Mirikizumab, based on the VIVID-1 trial outcomes, is a promising addition to CD therapy. It demonstrated significant clinical responses and remission rates, warranting further research on its long-term efficacy and safety. Updating professional guidelines and addressing affordability will ensure broader access and improved management of CD.
More Related Videos
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Drugs for Treatment of Ulcerative Colitis in IBD